Daniel Patrick O’day Sells 10,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $139.89, for a total transaction of $1,398,900.00. Following the sale, the chief executive officer owned 556,698 shares of the company’s stock, valued at approximately $77,876,483.22. The trade was a 1.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Daniel Patrick O’day also recently made the following trade(s):

• On Friday, January 23rd, Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00.
• On Monday, December 29th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $124.83, for a total value of $1,248,300.00.
• On Friday, November 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $126.54, for a total value of $1,265,400.00.

Gilead Sciences Stock Up 1.7%

Shares of NASDAQ GILD opened at $141.95 on Friday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The stock has a market capitalization of $176.11 billion, a PE ratio of 22.01, a P/E/G ratio of 0.73 and a beta of 0.33. Gilead Sciences, Inc. has a one year low of $93.37 and a one year high of $142.20. The business’s fifty day moving average price is $125.36 and its 200-day moving average price is $119.59.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.02 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Scotiabank began coverage on shares of Gilead Sciences in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price objective for the company. Rothschild & Co Redburn increased their target price on Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Sanford C. Bernstein set a $135.00 price target on Gilead Sciences and gave the stock an “outperform” rating in a report on Monday, December 29th. Morgan Stanley decreased their price objective on Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $135.00 price objective on shares of Gilead Sciences in a report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $136.36.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in GILD. Vanguard Group Inc. increased its stake in Gilead Sciences by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after acquiring an additional 2,113,692 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Gilead Sciences by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after acquiring an additional 727,515 shares during the last quarter. Norges Bank purchased a new position in shares of Gilead Sciences during the second quarter worth about $2,150,268,000. Invesco Ltd. increased its position in shares of Gilead Sciences by 12.0% in the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after purchasing an additional 1,618,453 shares during the last quarter. Finally, Amundi raised its stake in Gilead Sciences by 18.2% in the second quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock valued at $1,167,221,000 after purchasing an additional 1,614,355 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.